ALAMEDA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting
ALAMEDA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting
All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants. SLIM-1™ trial is a Phase 1, randomized, controlled clinical trial design to characterize
MIAMI, July 15, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 94th Emerging Growth Conference on July 15 & 16, 2026. The Emerging Growth
ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) (the "Company" or "Vivani"), an innovative, biopharmaceutical company developing novel, miniature, GLP-1 drug
MIAMI, July 14, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 94th Emerging Growth Conference on July 15 & 16, 2026. The Emerging Growth
ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), an innovative, biopharmaceutical company developing novel, ultra long-acting drug
ClearOne, Inc. (NASDAQ:CLRO) ("ClearOne") announced today that it has entered into a definitive agreement and plan of merger (the "Agreement") among its wholly-owned subsidiary ("MergerSub"),
Vivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (NASDAQ:CLRO), and change the listed company’s name and ticker to Cortigent Holdings, Inc. (d/b/a Cortigent) and "CRGT"
ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting
ALAMEDA, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting
ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting
ALAMEDA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants,
